Table 1.
Participants With Respiratory Syncytial Virus Infection, by World Health Organization Severity Level, From Vaccination Dose 1 Through Day 731a
| Infection Category | Participants in Pooled RSV Vaccine Groups (n = 43) | Participants in Pooled Placebo Groups (n = 39) | ||
|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | |
| No infection | 26 | 60.5 (44.4–75.0) | 24 | 61.5 (44.6–76.6) |
| Any RSV infection | 17 | 39.5 (25.0–55.6) | 15 | 38.5 (23.4–55.4) |
| ȃAsymptomatic | 7 | 16.3 (6.8–30.7) | 2 | 5.1 (.6–17.3) |
| ȃRTI | 10 | 23.3 (11.8–38.6) | 12 | 30.8 (17.0–47.6) |
| ȃAny LRTI | 0 | 0.0 (.0–8.2) | 1 | 2.6 (.1–13.5) |
| ȃSevere LRTI | 0 | 0.0 (.0–8.2) | 1 | 2.6 (.1–13.5) |
| ȃVery severe LRTI | 0 | 0.0 (.0–8.2) | 0 | 0.0 (.0–9.0) |
| ȃHospitalization | 0 | 0.0 (.0–8.2) | 0 | 0.0 (.0–9.0) |
| All-cause LRTIb | 8 | 18.6 (8.4–33.4) | 10 | 25.6 (13.0–42.1) |
Abbreviations: CI, confidence interval; LRTI, lower respiratory tract infection; RSV, respiratory syncytial virus; RTI, respiratory tract infection.
World Health Organization categories as outlined in reference [12].
Meeting the case definition for LRTI (Supplementary Table 5).